My SciELO
Custom servicesServices on Demand
Journal
Article
English (pdf)
Article in xml format
Article references
Automatic translation
Send this article by e-mailIndicators
Cited by SciELO 
Access statistics
Related links
Cited by Google 
Similars in
SciELO 
Similars in Google
Share
Permalink
Revista de la OFIL
On-line version ISSN 1699-714XPrint version ISSN 1131-9429
Abstract
BRICENO-CASADO, MP; RIOS-SANCHEZ, E and GIL-SIERRA, MD. Real long-term data of dupilumab in atopic dermatitis. Rev. OFIL·ILAPHAR [online]. 2020, vol.30, n.1, pp.25-27. Epub Jan 18, 2021. ISSN 1699-714X. https://dx.doi.org/10.4321/s1699-714x2020000100008.
Objectives:
Dupilumab is the first biological drug indicated in atopic dermatitis (AD). The aim of this study is to assess effectiveness and safety of dupilumab in moderate-severe AD in clinical practice, and the quality of life of treated patients.
Methods:
Descriptive retrospective study was conducted. Effectiveness was measured by SCORingAtopic Dermatitis (SCORAD). Primary endpoint was SCORAD-75; secondary endpoints were SCORAD-90 and “total clearance”, at week 4, 12, 24 and 48. Safety was evaluated according to adverse events profile. Quality of life was assessed by Dermatology Life Quality Index (DLQI) at week 0 and 48.
Results:
At week 4, 2 patients presented SCORAD-75, none presented SCORAD-90 or clearance. At week 12, 2 patients showed SCORAD-75, 2 SCORAD-90 and one clearance. At weeks 24 and 48, 3 patients presented SCORAD-90 and 3 clearance. All patients presented mild-moderate adverse events. DLQI at week 48 was 0.7.
Conclusions:
Dupilumab presented adequate effectiveness and safety, improving quality of life of treated patients.
Keywords : Atopic dermatitis; dupilumab; effectiveness; safety; quality of life.
